Jason Rhodes Sells 287,956 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 287,956 shares of Dyne Therapeutics stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a total transaction of $5,666,974.08. Following the completion of the sale, the director owned 11,663 shares in the company, valued at approximately $229,527.84. This trade represents a 96.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Down 3.9%

Shares of NASDAQ DYN opened at $18.90 on Friday. The firm has a fifty day simple moving average of $17.64 and a two-hundred day simple moving average of $18.37. Dyne Therapeutics, Inc. has a 12 month low of $8.06 and a 12 month high of $25.00. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $3.12 billion, a PE ratio of -5.34 and a beta of 1.29.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). Equities analysts expect that Dyne Therapeutics, Inc. will post -2.94 earnings per share for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

Several large investors have recently made changes to their positions in DYN. Hilton Head Capital Partners LLC purchased a new stake in shares of Dyne Therapeutics in the 1st quarter worth approximately $26,000. Chung Wu Investment Group LLC purchased a new position in Dyne Therapeutics during the third quarter valued at $30,000. Strs Ohio purchased a new position in Dyne Therapeutics during the fourth quarter valued at $51,000. Aster Capital Management DIFC Ltd bought a new stake in Dyne Therapeutics in the fourth quarter worth $84,000. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after acquiring an additional 2,465 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Chardan Capital reiterated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a report on Monday, March 9th. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday. Morgan Stanley reduced their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. Finally, HC Wainwright decreased their price objective on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $35.14.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.